Navigation Links
Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccine's Clinical & Regulatory Strategy
Date:1/3/2012

46% reduction in breast cancer recurrence in low HER2 expressing tumors together with excellent safety enables us to move forward in requesting an End-of-Phase II meeting with the FDA."

Importantly, the majority of women with loco-regional breast cancer have low to moderate expressing HER2 tumors and currently are treated with chemotherapy and radiotherapy only. There is no approved targeted HER2 therapy for these women.

"We are excited and committed to move the AE37 cancer vaccine through the appropriate scientific and regulatory steps," commented Mark Fletcher, President & Chief Executive Officer of Generex.  "AE37 not only continues to move closer to market approval but also provides validation for the underlying Ii-Key technology platform upon which it is based."

Phase I studies clearly identified the potential for AE37 to induce the immune system to focus on the HER2 protein through helper (CD4) and cytotoxic (CD8) immune cells in patients.  The HER2 protein is expressed on a high percentage of cancers in the breast, prostate, ovaries, gastro-intestinal tract, and lung.  In two Phase I trials, AE37 has demonstrated a good safety profile in both breast and prostate cancer patients.

The AE37 cancer vaccine has also completed a Phase 1 trial in prostate cancer demonstrating appropriate dosing and immune activation similar to that seen in the breast cancer trials.  The Phase 2b breast trial results add to AE37's database on tolerability and safety and have raised the possibility of using AE37 early in prostate cancer therapy.  With the Phase 2b breast cancer trial suggesting immune activation by AE37 could control breast cancer and seeing similar immune activation in the Phase I prostate trial, the Company is encouraged to move AE37 cancer vaccine more rapidly into larger clinical trials in men with newly diagnosed HER2 positive prostate cancer.  These Phase 2 trials are being designed with leading onc
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
2. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
3. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
4. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
5. Generex Provides Update on Spinout of Antigen Express
6. Generex Augments Cash Position With Sales of Non-Essential Assets
7. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
8. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
9. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
10. Generex Provides Clarification of Facts
11. Generex Announces Results of Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 30, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... that it has commenced an underwritten public offering of ... the underwriters a 30-day option to purchase up to ... stock offered in the public offering. The offering is ... assurance as to whether or when the offering may ...
(Date:4/30/2015)...  The Paul G. Allen Family Foundation announced today ... six groups of researchers with projects at the frontier ... growing mature human brain cells in the laboratory. The ... over three years.  "This new cohort ... significant because the field of neuronal maturation is at ...
(Date:4/30/2015)... FRANCE (PRWEB) April 30, 2015 ... and at http://www.lespausa.com , Fleur’s ... multi-action product combining the benefits of makeup, skin ... This subtly tinted cream is designed with specific ... for an even complexion and a healthy glow. ...
(Date:4/29/2015)... According to a new market research report ... Non-Portable), Component (Accelerometer, Proximity Probe, & Others), Application ... & Others), & Geography - Global Forecast to ... $1,453.76 Million by 2020, at a CAGR of ... 92 figures spread through 205 pages and in-depth ...
Breaking Biology Technology:BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4
... Aug. 10, 2011 Genesis Biopharma, Inc. (OTC/BB: ... today announced it has signed a Cooperative Research ... Institute (NCI).  Under the terms of the five-year ... work with Steven A. Rosenberg, M.D., Ph.D., the ...
... Accuray Incorporated (Nasdaq: ARAY ), the premier ... to present at the Wedbush Life Sciences: Management Access Conference ... a.m. ET/6:10 a.m. PT. A live webcast of ... page of the Company,s Web site at http://www.accuray.com . ...
... YORK, Aug. 9, 2011 Reportlinker.com ... report is available in its catalogue: ... Market: Facilities, Test Volumes, and Sales ... http://www.reportlinker.com/p0591318/Global-Microbiology-Testing-Market-Facilities-Test-Volumes-and-Sales-Forecasts-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic This ...
Cached Biology Technology:Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 2Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 3Global Microbiology Testing Market: Facilities, Test Volumes, and Sales Forecasts by Country 2
(Date:4/21/2015)... Canada , April 21, 2015 ... and evolving government policies are boosting access control systems ... According to a recently published report by ... Opportunities, 2020 ", the access control systems market in ... nearly USD1.2 billion by 2020.The access control systems market ...
(Date:4/20/2015)... April 20, 2015 The announcement ... Glenbeigh Records Management (GRM), Ireland,s ... Islamic Bank. Having built up an impressive track record of ... leading player within the records management sector in ... double is GCC staffbase and employ a further eight staff ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... available in French . , Pears ... are microscopically small structures for oxygen supply and are ... the Catholic University of Leuven in Belgium and the ... the first time, therefore proving their hypothesized existence. In ...
... be a significant step closer to climbing into the driver,s ... Washington University School of Medicine in St. Louis report in ... single protein, HS1, enables key functions of natural killer (NK) ... The protein allows the NK cells to pursue their targets, ...
... a leading supplier of broadband technology and biometrics software,has ... results,for the second quarter of 2008 on Thursday, July ... and CFO Rick Moberg will host the,earnings conference call., ... can be accessed on the,Investor Relations page of our ...
Cached Biology News:Comparing apples and pears 2Control switches found for immune cells that fight cancer, viral infection 2Aware Announces Q2 2008 Earnings Conference Call 2
... Capillary Electrophoresis Running Buffer was designed to ... demands of todays sequencing labs. As a ... to the gel-based sequencing community Sigma has ... to meet your buffer needs. Scientists at ...
... The ProteomeLab PA 800 is ... Part of Beckman Coulters ProteomeLab ... offers a comprehensive range of automated ... determination, peptide mapping, isoelectric focusing, carbohydrate ...
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... Jobin Yvons Protein 295 ex can measure ... sample in only a few minutes. To ... acids tyrosine and tryptophan, the Protein 295 ... a pulsed diode emitting 295 nm. Fluorescence ...
Biology Products: